Funding biotech: Do we need a superfund?

Jan 14, 2013 Tags: Biotech Pharma Investment

Last year Mark Kessel called for the establishment of a biotech superfund funded by pharma, outlining the capital crisis faced by the biopharma industry and its negative impact on innovative therapies. He wrote that a superfund, modeled after the successful SEMATECH superfund, is a viable tool to address the need to fund innovation. This panel discusses the capital crisis, its effect on innovation and the possibility of creating a superfund.

Moderator: Brady HuggettNature Publishing Group